ANTENGENE CORP. DL-0001(722)

Description: Antengene Corporation Limited, a biopharmaceutical company, engages in the development of novel oncology therapies in Greater China and internationally. The company's commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients in Mainland China, Singapore, Australia, Hong Kong, Macau, and Taiwan. Its late-stage products candidates comprise ATG-008 (onatasertib), an mTOR kinase inhibitor for the treatment of cervical cancer and other advanced solid tumors. The company also develops other clinical stage assets, such as ATG-016, a second generation XPO1 inhibitor, which is in Phase II open-label study in patients with patients with high-risk myelodysplastic syndromes; ATG-017, an ERK1/2 inhibitor for the treatment of advanced/metastatic solid tumors and hematologic malignancies; ATG-101, a PD-L1/4-1BB bispecific antibody, which is in Phase I study for patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma; ATG-037, an CD73 inhibitor for patients with advanced or metastatic solid tumors; ATG-018, an ATR inhibitor; ATG-022, a Claudin 18.2 antibody-drug conjugate; and ATG-031 an anti-CD24 monoclonal antibody. In addition, its pre-clinical stage assets consist of ATG-042, an PRMT5-MTA inhibitor and ATG102, an LILRB4 x CD3 T cell engager. Further, it develops AnTenGager, an 2+1 T cell engager platform which enables conditional T cell activation with reduced risk of cytokine release syndrome; and engages in the trading activities. Antengene Corporation Limited was founded in 2017 and is based in Shanghai, China.

---

Keywords: Biopharmaceutical Solid Tumors Lymphoma Antineoplastic Drugs Orphan Drug Multiple Myeloma Hematologic Malignancies Hematological Malignancies Advanced Solid Tumors Cervical Cancer Hodgkin Metastatic Solid Tumors Oncology Therapies Teratogens Antibody–Drug Conjugate Relapsed/Refractory Multiple Myeloma Atg Diffuse Large B Cell Lymphoma Triazoles Relapsed/Refractory Diffuse Large B Cell Lymphoma Selinexor Treatment Of Cervical Cancer Cytokine Release Syndrome Pyrazines Advanced/Metastatic Solid Tumors Metastatic/Advanced Solid Tumors Selective Inhibitor Of Nuclear Export

---

Home Page: www.antengene.com

Zhongshan SOHO Plaza
Shanghai, 200051
China
Phone: 86 21 2356 6665

---

Officers

Exchange: F

Country: DE : Germany

Currency: Euro (€)